A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.

A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.

PURPOSE: Real-time symptom monitoring using a mobile phone is potentially advantageous for patients receiving oral chemotherapy. We therefore conducted a pilot study of patient dose adaptation using mobile phone monitoring of specific symptoms to investigate relative dose intensity of capecitabine,...

Full description

Bibliographic Details
Main Authors:	Weaver, A, Love, S, Larsen, M, Shanyinde, M, Waters, R, Grainger, L, Shearwood, V, Brooks, C, Gibson, O, Young, A, Tarassenko, L
Format:	Journal article
Language:	English
Published:	2014

Similar Items

Chemotherapy side-effect management using mobile phones.
by: Larsen, M, et al.
Published: (2008)

Management of severe capecitabine-induced corneal toxicity
by: Mathieu Heyvaert, et al.
Published: (2024-12-01)

Mobile health for drug dose optimisation.
by: Larsen, M, et al.
Published: (2011)

Mobile health for drug dose optimisation.
by: Larsen, M, et al.
Published: (2011)

Application of mobile phone technology for managing chemotherapy-associated side-effects.
by: Weaver, A, et al.
Published: (2007)

Capecitabine: have we got the dose right?
by: Midgley, R, et al.
Published: (2009)

Capecitabine: Have we got the dose right?
by: Midgley, R, et al.
Published: (2009)

Capecitabine: Have we got the dose right?
by: Midgley, R, et al.
Published: (2009)

Mobile phone technology for managing chemotherapy associated side-effects
by: Young, A, et al.
Published: (2008)

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
by: Kerr, R, et al.
Published: (2016)

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial
by: Love, S, et al.
Published: (2016)

CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL
by: Midgley, R, et al.
Published: (2012)

A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer
by: Trish Millard, et al.
Published: (2024-01-01)

Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib
by: Elia Romero Carreño, et al.
Published: (2016-03-01)

Ileitis Secondary to Oral Capecitabine Treatment?
by: Rami Radwan, et al.
Published: (2012-01-01)

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
by: Rosmarin, D, et al.
Published: (2014)

GDm-Health: a pilot study examining acceptability of mobile phone assisted remote blood glucose monitoring for women with gestational diabetes
by: Loerup, L, et al.
Published: (2014)

GDm-Health: A Pilot Study Examining Acceptability of Mobile Phone Assisted Remote Blood Glucose Monitoring for Women with Gestational Diabetes Mellitus
by: Hirst, J, et al.
Published: (2014)

Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma
by: Thomas, A, et al.
Published: (2019)

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS.
by: Rosmarin, D, et al.
Published: (2015)

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS
by: Rosmarin, D, et al.
Published: (2015)

GDm-Health: a pilot study demonstrating the feasibility of mobile phone assisted treatment advice and medication adjustment for women with gestational diabetes
by: Loerup, L, et al.
Published: (2014)

Assessment of Oral Capecitabine in Elderly Patients with Stage 2 Colon Cancer: Toxicity, Tolerability, and Survival Outcomes
by: Ezgi Değerli, et al.
Published: (2024-11-01)

Toxicity, tolerability & compliance of concurrent capecitabine or 5-fluorouracil in the radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort
by: Jones, C, et al.
Published: (2018)

Mobile phone technology in the management of asthma.
by: Ryan, D, et al.
Published: (2005)

Capecitabine/irinotecan combination regimens in colorectal cancer.
by: Kerr, D
Published: (2002)

Adherence and safety study in patients on treatment with capecitabine
by: Francisca Fernández-Ribeiro, et al.
Published: (2017-03-01)

Oral Capecitabine Achieves Response in Metastatic Eccrine Carcinoma
by: Kristian Larson, et al.
Published: (2018-01-01)

Questions asked and answered in pilot and feasibility randomized controlled trials.
by: Shanyinde, M, et al.
Published: (2011)

Capecitabine and streptozocin ± cisplatin for gastroenteropancreatic neuroendocrine tumours: predictors of long-term survival in the NET01 trial
by: Meyer, T, et al.
Published: (2016)

A Phase I dose-finding and safety study of AZD8931 with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma: the randomised expansion phase of the DEBIOC trial
by: Thomas, A, et al.
Published: (2018)

Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma
by: Gehan Abd Elatti Khedr, et al.
Published: (2016-06-01)

SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
by: Virdee, P, et al.
Published: (2017)

An optimised algorithm for accurate steps counting from smart-phone accelerometry
by: Salvi, D, et al.
Published: (2018)

Case report: A case of severe capecitabine toxicity due to confirmed in trans compound heterozygosity of a common and rare DPYD variant
by: Amy de Haar-Holleman, et al.
Published: (2024-09-01)

A real-time, mobile phone-based telemedicine system to support young adults with type 1 diabetes.
by: Farmer, A, et al.
Published: (2005)

CAN YOUR MOBILE PHONE IMPROVE YOUR ASTHMA?
by: Ryan, D, et al.
Published: (2010)

CAPECITABINE IN THE TREATMENT OF BRAIN METASTATIC LESION IN PATIENTS WITH BREAST CANCER
by: E. A. Moskvina, et al.
Published: (2015-04-01)

Hyperammonemia after capecitabine associated with occult impairment of the urea cycle
by: Gilbert Chu, et al.
Published: (2019-05-01)

A 5-Fluorouracil-Induced Hyperammonemic Encephalopathy Challenged with Capecitabine
by: Michael Chahin, et al.
Published: (2020-01-01)